Multiple sclerosis

Shilpa Klocke, PharmD, BCPS
Nicole Hahn, PharmD, BCACP

How to cite: Klocke S, Hahn N. Multiple sclerosis. Ment Health Clin [Internet]. 2019;9(6):349-58. DOI: 10.9740/mhc.2019.11.349.

Abstract
Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis.

Keywords: multiple sclerosis, disease-modifying therapies, escalation versus induction, highly effective, modestly effective, guidelines

Introduction
Multiple sclerosis (MS) is characterized by immune-mediated, demyelinating attacks on the central nervous system (CNS) resulting in fully or partially reversible neurologic syndromes or relapses. An MS relapse typically comes on acutely or subacutely, lasts days to weeks, and gradually remits. Radiographic evidence of inflammatory attacks can be seen anywhere in the white and grey matter of the CNS. Symptoms reflect lesion locations although silent lesions occur as well. Acute optic neuritis is the most common neurologic syndrome at onset. Other symptoms may occur throughout the disease such as cognitive impairment, fatigue, bowel and bladder disturbances, and spasticity.

Epidemiology, Phenotypes (Clinical Course), and Diagnosis
Nearly one million persons are currently living with MS in the United States. Multiple sclerosis is most commonly diagnosed in females and at age 20 to 50 years. More than 80% of persons with MS (pwMS) have relapsing remitting MS (RRMS). Approximately 15% to 30% of pwMS will gradually evolve from RR to secondary progressive (SP) 15 to 20 years after onset. Previous natural history studies reported that 25% to 40% of pwMS develop SPMS, likely reflecting the lack of earlier diagnosis and use of DMTs. Roughly 15% of pwMS have a primary progressive (PP) course from the onset.

A relapsing or progressive phenotype has been used since 1996 to describe a person’s MS. In 2013, these phenotypes were modernized to better inform prognostication and
treatment decision making by addressing limitations of the older phenotypes (Table 1). The core clinical phenotypes of RR, SP, PP were retained, clinically isolated syndrome was officially added, but the confusing progressive relapsing phenotype was removed. Radiologically isolated syndrome or the incidental findings of MS-like lesions on brain magnetic resonance imaging (MRI), was not added since MRI findings without clinical evidence of demyelination may be nonspecific. Descriptive modifiers were introduced to provide more clinically useful information when communicating phenotype including active and not active to describe disease activity (recent relapse or CNS imaging activity) and with progression and without progression to describe disease worsening. As of May of 2019, the Food and Drug Administration (FDA) approved labeling of every DMT has been updated with these modifiers.

The McDonald’s diagnostic criteria routinely undergoes revisions aligning the criteria with advancements in clinical and imaging technologies. Diagnosis is based on parameters such as medical history and neurological exam, as well as paraclinical parameters such as MRI, cerebrospinal fluid showing oligoclonal banding (sign of CNS inflammation), and evoked potentials (a measure of electrical activity in the brain). MRI remains the most sensitive tool available for determining events that meet diagnostic criteria for dissemination in time and space. The 2017 McDonald’s diagnostic criteria revision allows for earlier diagnosis of MS in individuals with typical clinically isolated syndrome if either imaging shows both symptomatic and asymptomatic MRI lesions or if cerebrospinal fluid is positive for oligoclonal banding. MRI scans may be used to obtain objective evidence to track treatment efficacy and adverse effects (Table 2).

### Patient Case Part 1: Risk Factors

A 27-year-old presents to the clinic with new onset numbness and tingling of the left buttock, leg, and foot along with lightheadedness and fecal incontinence. Brain MRI showed 2 new T2-lesions and cervical spine MRI showed 1 new T2-lesion, resulting in a diagnosis of RRMS. The patient exercises 4 times weekly, smokes 1 pack per day, has 2 to 3 alcoholic beverages per month, and expresses interest in natural remedies and lifestyle changes when discussing treatment options.

The incidence of MS in the United States is greater at higher latitudes. This prevalence gradient may be related to less ultraviolet B-induced vitamin D production in the skin due to less sun exposure. Vitamin D appears to have protective anti-inflammatory and immunoregulatory effects. Other immunologic, infectious, genetic, and environmental etiological factors have also been identified. Patients should be educated on the etiological factors that are modifiable if applicable, where interven-

### TABLE 1: The 2013 update to the phenotypic classifications of MS

| Terminology | Definition |
|-------------|------------|
| Relapsing remitting (RR) | Characterized by relapses from onset that are partially or completely reversible. |
| Secondary progressive (SP) | Gradual progression (disability accumulation) following an initial relapsing disease course. |
| Primary progressive (PP) | Gradually evolving progression without discrete relapses. |
| Clinically isolated syndrome (CIS) | The first neurologic syndrome lasting at least 24 hours with or without lesions on magnetic resonance imaging (in an MS-like distribution). |
| Radiologically isolated syndrome (RIS)<sup>a</sup> | Incidental findings of lesions occurring in an MS-like distribution. |

MS = multiple sclerosis.

<sup>a</sup>Not considered an official MS phenotype as of 2013 update.
tion may either lower the risk of developing MS or if diagnosed, may weaken its influence on the rate of disease progression (Table 3).13,14

Predicting the course of a pwMS is difficult since the disease manifests heterogeneously from one individual to another. Several factors can discern which pwMS may be at greater risk for a more aggressive course.15,16 The strongest and most consistent negative prognostic factors include: frequent relapses during the first 2 to 5 years postonset, short interval between relapses, incomplete relapse recovery, sphincter-type symptoms (ie, bowel, bladder), progression at onset, and rapidly worsening disability.15,16 Imaging characteristics include increasing size of T2 lesion burden from baseline, GAD lesions, cerebellar and/or spinal cord lesions, and brain atrophy.16 Identifying the presence of negative prognostic factors and, thereby, patients at greater risk of disease worsening, informs clinicians which patients may benefit from earlier initiation of higher efficacy DMT.

**Patient Case Part 2: Too Many Choices**

Based on formulary options, copay assistance programs, and patient preference for route of administration, interferon-betas, fingolimod, and teriflunomide are DMT options discussed with the patient during a shared-decision making conversation.

**Personalizing Treatment**

The newer DMTs affect immune system functioning more directly compared to older self-injectable DMTs by targeting T-cell activation, T-cell migration, T- and/or B-cell depletion. When selecting a DMT, consider patient-specific factors and treatment approach. In the case example, affordability as well as oral and injectable options were discussed given the patient did not want to consider an infused therapy option. Although self-injectable interferon-betas were the mainstay of MS management for many years, the self-injectable adminis-

| Terminology                      | Definition                                                                                           |
|----------------------------------|------------------------------------------------------------------------------------------------------|
| T1-weighted without GAD          | Hypointense or dark areas on magnetic resonance imaging. Considered to be areas of permanent damage or neurodegeneration. Sometimes called T1-black holes. |
| T1-weighted with GAD             | Hyperintense or enhancing lesions. Consider to be areas where the blood brain barrier has broken down and acute inflammation has occurred. |
| T2-weighted                      | Images showing all new and old lesions.                                                               |
| FLAIR                            | Similar to the T2-weighted image, but increases the detection of new lesions without interference from cerebrospinal fluid. |
| Brain atrophy                    | Shows overall reduction in volume of both white and gray matter.                                       |
| Spinal cord                      | Assists with showing dissemination in time and space.                                                    |

**TABLE 3: Potentially modifiable environmental etiologic factors**

- Individuals with decreased cutaneous production or consumption of vitamin D
  - Increased risk of relapses
  - Empirc vitamin D3 is 800 IU to 4000 IU daily is recommended
- Tobacco smoking
  - Progress to secondary progressive MS at a faster rate than non-smokers with greater risk of increasing disability
  - May not achieve optimal benefit of MS disease-modifying therapies
  - Quitting smoking delays experiencing disability progression and lessens the influence on relapses.
- Obesity
  - Occurring especially during childhood and adolescence (and in females) increases the risk for developing MS and for disease activity in persons with MS

MS = multiple sclerosis.
**TABLE 4: Disease-modifying therapies**

| Name of Drug | Route of Administration | Mechanism of Action | Indication | Adverse Effects | Monitoring | Author Clinical Pearls and Other Highlights |
|--------------|-------------------------|---------------------|------------|----------------|-----------|---------------------------------------------|
| **ME-DMT**   |                         |                     |            |                |           |                                             |
| Interferon-betas | SC, IM                  | Reduce activation and entry of T cells into central nervous system; reduces adhesion molecules and helper T cells | Relapsing forms of MS | Common: ISR, flu-like symptoms, Less common: depression, abnormalities, abnormalities in CBC, LFTs, TFTs | Baseline: CBC, LFTs, TSH | Routine: CBC, LFTs, TSH | Encourage hydration to reduce severity/frequency of flu-like symptoms |
| Glatiramer acetate | SC                      | Copolymer mimics myelin basic protein triggers shift toward type 2 helper T cells | Relapsing forms of MS | Common: ISR, lipoatrophy, Less common: transient 15 to 30 min postinjection reaction (anxiety, chest pain, palpitations, flushing) | None | FDA-approved generics available |
| **ME-DMT or HE-DMTa** |                       |                     |            |                |           |                                             |
| Dimethyl fumarate | PO                     | Antioxidant and anti-inflammatory effects mediated through nuclear factor 2 pathway | Relapsing forms of MS | Common: flushing, nausea, diarrhea, abdominal pain, Less common: lymphopenia, elevated LFTs, rash | Baseline: CBC, LFTs | Routine: CBC, LFTs | Consider interruption of therapy if ALC less than 500/l for more than 6 mo |
| Teriflunomide | PO                      | Inhibits pyrimidine synthesis; prevents proliferation of T-cells and B-cells | Relapsing forms of MS | Common: alopecia, diarrhea, nausea, paresthesia, nasopharyngitis, Less common: leukopenia, increased BP, hepatotoxicity | Baseline: CBC, LFTs, BP | pregnancy test, TB test | Routine: alanine transaminase monthly for first 6 mo, then LFTs and/or CBC as needed |
| **HE-DMT**   |                         |                     |            |                |           |                                             |
| Alemtuzumab | IV                      | Anti-CD52 monoclonal antibody decreases B-cells and T-cells | Relapsing forms of MS for patients with an inadequate response to 2 or more DMTs | Common: URI, nasopharyngitis, nausea, vomiting, urinary tract infection, fatigue, URI, herpes viral infections, urticaria, pruritus, secondary thyroid autoimmunity, fungal infection, arthralgia, diarrhea, paresthesia, rash | Baseline: CBC, LFTs, SCr, UA, TFT, skin examination, VZV serology, TB test, HIV screen, pregnancy test | REMS required monitoring: Starting after the first infusion series and for 48 mo after last treatment cycle: CBC, SCr, UA monthly, TSH every 3 mo, skin examination yearly | Low PML riskb |
| Cladribine | PO                      | Purine nucleoside analog; selectively depletes peripheral lymphocytes | RRMS and active SPMSc for patients who have had inadequate response to, or unable to tolerate, at least 1 other DMT | Common: URI, headache, nausea, lymphopenia, Less common: liver injury, infections, opportunistic infections, nephrotoxicity, severe dermatologic reactions, malignancy | Baseline: CBC, TB, HIV and hepatitis B screen, pregnancy test, LFTs | Between/after treatment courses: CBC 2 and 6 mo after start of each treatment course, LFTs if clinically indicated | Administer anti-herpes prophylaxis if ALC <200/μL |

b Low PML risk is observed in observational studies.

c Effective contraception is required.

d Avoid if pregnancy desired given teratogenicity concerns.

Ment Health Clin [Internet]. 2019;9(6):349-58. DOI: 10.9740/mhc.2019.11.349 352
TABLE 4: Disease-modifying therapies17-29 (continued)

| Name of Drug | Route of Administration | Mechanism of Action | Indication | Adverse Effects | Monitoring | Author Clinical Pearls and Other Highlights |
|--------------|-------------------------|---------------------|------------|----------------|-----------|------------------------------------------|
| Fingolimod   | PO                      | S1P nonselective receptor modulator; sequesters lymphocytes in lymphoid tissue | Relapsing forms of MS | Common: headache, diarrhea, back pain, elevated LFTs, cough, lymphopenia | Baseline: CBC, LFTs, VZV serology, OCT test, ECG, BP pulse | Must discontinue 2 mo prior to trying for conception |
|              |                         |                     |            | Less common: bradycardia, AV conduction slowing, HSV infections, macular edema, asthma exacerbation, seizure, BCC, melanoma | Initiation: FDO; observe for bradycardia for 6 h after first dose monitoring pulse, BP and ECGs | Risk of severe MS rebound with discontinuation |
| Natalizumab  | IV                      | Selective adhesion molecule inhibitor; prevents migration of inflammatory cells across blood brain barrier | Relapsing forms of MS | Common: rash, arthralgia, headache, respiratory tract infection | Routine: CBC, LFTs; OCT 3 to 4 mo after starting | FDA approved for 10 y and older, with dose adjustment |
|              |                         |                     |            | Less common: PML, leukocytosis, hepatotoxicity | Baseline: CBC, LFTs, anti-JCV antibody | Low PML riskb |
| Ocrelizumab  | IV                      | Anti-CD20 humanized monoclonal antibody; depletes B-cells | Relapsing forms of MS, PPMS | Common: IRR, infection | Baseline: HBV screening, CBC immunoglobulins | Avoid or use with caution in persons with skin cancers |
| Rituximab    | IV                      | Anti-CD20 chimeric monoclonal antibody; depletes B-cells | Relapsing forms of MS | Common: IRR, infection | Baseline: HBV screening, CBC immunoglobulins | Highest risk of PML for all DMTs |
|              |                         |                     |            | Less common: hypogammaglobulinemia, hepatitis B reactivation | Routine: CBC, immunoglobulins as needed | Risk is directly associated to anti-JCV antibody positive status, duration of therapy, and history of immunosuppressant use |
|              |                         |                     |            | hepatitis B reactivation | Routine: anti-JCV antibody every 6 mo (per REMS); CBC, LFTs as needed | Avoid use if anti-JCV antibody positive |
|              |                         |                     |            |                         | Initiation: FDO only if presence of skin cancers | May monitor B-cells |
|              |                         |                     |            |                         | Despite increased receptor selectivity, risk of adverse effects appears similar to fingolimod | Low PML riskb |
|              |                         |                     |            |                         | Starter pack with slow dose titration reduces need for FDO requirement | May monitor B-cells |
| Sirolimus    | PO                      | S1P nonselective receptor modulator; sequesters T-cells in lymphoid tissue | Relapsing forms of MS | Common: headache, hypertension, elevated LFTs | Baseline: CYP2C9 genotype, CBC, LFTs, VZV serology, OCT test, ECG, BP pulse | Suspect rebound will be a concern here too (given mechanism of action) and risk of skin cancers |
|              |                         |                     |            | Less common: bradycardia, AV conduction slowing, HSV infections, macular edema, asthma exacerbation, risk of BCC | Initiation: FDO only if presence of heart block, sick sinus syndrome or pacemaker | FDA approved for 10 y and older, with dose adjustment |
|              |                         |                     |            |                         | Routine: CBC, LFTs, OCT 3 to 4 mo after starting | Low PML riskb, no cases of PML |

ALC = absolute lymphocyte count; AV = ativoventricular; BCC = basal cell carcinoma; BP = blood pressure; CBC = complete blood count; DMT = disease-modifying therapy; ECG = electrocardiogram; FDA = Food and Drug Administration; FDO = first dose observation; Gl = gastrointestinal; HBV = hepatitis B virus; HE = highly effective; HIV = human immunodeficiency virus; HSV = herpes simplex virus; IM = intramuscular; IRR = infusion related reaction; ISR = injection site reactions; ITP = immune thrombocytopenic purpura; IV = intravenous; JCV = John Cunningham virus; LFTs = liver function tests; ME = modestly effective; MS = multiple sclerosis; OCT = optical coherence tomography; PML = progressive multifocal leukoencephalopathy; PO = oral; PP = primary progressive; REMS = Risk Evaluation and Mitigation Strategy; RR = relapsing remitting; S1P = sphingosine 1-phosphate; SC = subcutaneous; Scr = serum creatinine; SPMS = secondary progressive multiple sclerosis; TB = tuberculosis; TFT = thyroid function test; UA = urinalysis; URI = upper respiratory infection; V2Z = varicella zoster virus.

*ME-DMT and HE-DMT classification is controversial. Higher efficacy outcomes in clinical trials appear to not always correlate to what’s seen in clinical practice or observational studies. For this reason, these DMTs are listed as they are in this table.

The vast majority of PML cases occur in patients previously exposed to natalizumab. For some, the switch from natalizumab was prompted by an anti-JCV antibody positive status and/or more than 2 years of treatment. In cases of no prior natalizumab exposure, some PML cases were associated rarely with severe lymphopenia (as with dimethyl fumarate) or with prior history/concomitant use of immunosuppressing therapies. For these reasons, risk of PML for natalizumab DMTs is overall considered to be low.

Relapsing forms of MS are considered to be clinically isolated syndrome, RRMS, and active SPMS per the 2013 update in MS phenotypes. While it may appear that siponimod and cladribine were the first DMTs to be approved for use in SPMS, that is not the case as patients meeting the definition for active SPMS, a relapsing form of MS, were enrolled in these clinical trials. With the phenotype updates, all package labeling of DMTs for relapsing MS were updated in May of 2019 to include active SPMS as a relapsing form.
Determining Modestly Effective Versus Highly Effective DMTs

The variable efficacy and side effect profiles of currently approved DMTs (Table 4) have introduced the idea of personalizing MS care.

Based on the available evidence, there is a generally accepted categorization of modestly effective (ME)-DMTs versus highly effective (HE)-DMTs (Table 4), however controversy and differences in clinical opinion still exists. The increased efficacy of many of the newer DMTs exposes pwMS to DMTs with higher risks (eg, adverse effect potential, more complex safety monitoring needed). This increased risk potential is related to the newer agents having more immunosuppressing mechanisms (suppressing the immune response) versus the immunomodulating mechanisms (adjusting level of immune response) of the first available DMTs.

Determining ME-DMT versus HE-DMT for relapsing type of MS is not entirely straightforward given an overall lack of head-to-head trials between newer and older DMTs. Previous head-to-head trials between older self-injectable agents have shown similar efficacy across agents. While one trial showed superiority of one interferon-beta over another (eg, high-dose interferon vs low-dose interferon) this trial had design limitations lessening the strength of the result. The available phase III head-to-head trials and comparative effectiveness research between interferon-betas and the oral DMTs suggest teriflunomide is as effective as the interferon-betas and fingolimod is more effective than interferon-betas. The placebo-controlled studies of dimethyl fumarate included glatiramer acetate as a reference comparator, and thus were not designed to test the superiority or noninferiority of dimethyl fumarate versus glatiramer acetate. Prospective head-to-head studies among the HE-DMTs remain absent. Fortunately, observational and comparative effectiveness studies showing HE-DMTs are more effective than ME-DMTs and describing long-term safety are providing real world data and supplementing the evidence given the limited number of head-to-head phase III trials.

With limited head-to-head data, clinicians are also left with comparing DMT efficacy outcomes such as annualized relapse reduction, incidence of new brain lesions on MRI, and disability scores, across placebo-controlled clinical trials. This practice comes with its own set of confounding factors and limitations making it difficult to compare these agents. For example, clinical trials vary by patient population and inclusion/exclusion criteria. Additionally, the diagnostic criteria for MS and definition of clinical relapse have changed and evolved over the years, making it difficult to compare recent studies to older clinical trials.

Patient Case Part 3: To Induce or Not to Induce

At the next clinic visit, the clinician and the patient discussed the goals and expectations of therapy and compared the efficacy and safety of the DMT options.

Given the approval of more efficacious DMTs, a broad evolution of the current MS treatment paradigm is underway. The key evolving concepts include treatment initiation and goals, stratifying treatment on disease phenotype and DMT efficacy, and managing use of riskier DMTs.

Goals of Treatment and Treatment Strategy

Prior to the availability of HE-DMTs, treatment response was demonstrated by achieving limited reduction in relapse rates and minimal effects on disability accumulation. Following the approval of HE-DMTs, the goals of treatment response have started to shift from reluctant acceptance of a partial response to the expectation of achieving as close to complete cessation of disease activity and progression as possible. The no evidence of disease activity (NEDA) treatment goal remains controversial because of a lack of definition for how to measure disability progression clinically, MRI sensitivity for detecting lesions associated with disability, and real-world application. The most agreed upon definition includes the absence of relapses, no confirmed disability progression, and no new GAD lesions or new or worsened T2 lesions. Using NEDA as a treatment goal means any evidence of relapse, progression, and/or active lesions should prompt reconsideration of the current DMT. Two therapeutic strategies are being examined to determine which best achieves a NEDA-like target.

The escalation strategy means starting with safer ME-DMTs and then transitioning to higher risk HE-DMTs only if disease breakthrough occurs. The argument against this strategy is that the early use of subpotent DMTs may expose individuals unnecessarily to the loss of functional years from disability accumulation because relapses are frequently underreported and silent lesions often occur.

The induction strategy means that the higher risk, HE-DMTs are started immediately following diagnosis, in order to achieve the NEDA-like target as early as possible. Alemtuzumab and cladribine are considered induction-specific DMTs given their relatively rapid suppression of
multiple cell lines and persistent immunosuppression. Repopulation of these cell lines may take months to years thus, fostering long term suppression of disease activity. Induction therapy is then followed by long-term maintenance treatment, such as with a ME-DMT.\textsuperscript{50} Rituximab and ocrelizumab are also HE-DMTs, though these agents have partial induction effects. While they do not suppress multiple immune cell lines, their duration of effect is prolonged and repeat dosing can be given at extended intervals (ie, every 9 to 12 months or longer if needed) over time. Natalizumab and fingolimod are HE-DMTs and are used as initial treatments for aggressive disease in a manner similar to induction-specific DMTs, but they do not have true induction effects. Both natalizumab and fingolimod (and likely siponimod) appear to have rapidly reversible effects that predispose patients to a rebound of disease activity upon discontinuation.\textsuperscript{50} The overall concern with the induction approach is that an otherwise young, healthy person may be exposed to serious adverse effects including risk of opportunistic infections.

The recently updated treatment guidelines published by the American Academy of Neurology (AAN)\textsuperscript{51} and the European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) in cooperation with the European Academy of Neurology (EAN)\textsuperscript{53} do not advocate for any particular therapeutic strategy. Both advise treating individuals with clinically isolated syndrome who have MS-like lesions with an injectable DMT. Both recommend treating RRMS as early as possible to improve outcomes based on data from trials of individuals with clinically isolated syndrome who had MS-like lesions and trials showing DMT efficacy is greatest when using the HE DMTs early in the disease.\textsuperscript{33,52,53} And both guidelines address switching DMTs. EAN/ECTRIMS endorses switching therapy for pwMS on a self-injectable who experience breakthrough disease activity (relapses, disability progression, or MRI activity) to a HE-DMT rather than between self-injectables. Without providing a definition of highly active MS, the AAN advises identifying persons with highly active MS and treating individuals with DMTs they consider having greater efficacy but did not use the term highly effective.\textsuperscript{51} Neither of these guidelines provide specific treatment algorithms for personalization. The MS Coalition, an affiliation of independent MS organizations including the National Multiple Sclerosis Society, updated their consensus paper in 2019. The consensus paper\textsuperscript{1} advocates for initiating DMT early, recognizes specific DMTs as HE-DMTs and supports using HE-DMTs if disease is highly active and opposes any restrictions to therapy choice. Neither AAN nor EAN/ECTRIMS guidelines support one strategy (escalation or induction) over the other, and both strategies are an option. Use of a ME-DMT at onset (escalation strategy) can be considered either for patients presenting with milder symptoms (ie, optic neuritis or numbness/tingling sensory symptoms), who have no negative prognostic factors, for patients already stable on ME-DMTs who have no negative prognostic factors, or for patients who are risk averse. Consider escalating to a HE-DMT when a new relapse and/or new MRI lesion(s) occur. Additionally, inform the patient that even though the disease may appear dormant, silent inflammatory attacks and progression may be ongoing.\textsuperscript{55,56} For pwMS with any negative prognostic factor, we suggest HE-DMT from the start (induction strategy) along with education of the risks and careful monitoring of side effects.

### Patient Case Part 4: De-Risking the Risk

The clinician supports the choice of fingolimod as an induction therapy given findings of spinal cord lesions and sphincter symptoms (fecal incontinence). Appropriate screening is completed and fingolimod is initiated with the recommended first dose observation (FDO) including a baseline electrocardiogram, blood pressure, and heart rate followed by blood pressure and heart rate checks hourly for 6 hours after the first dose is taken, and finally a repeat electrocardiogram at the 6 hour mark. The FDO of fingolimod is tolerated and treatment is started, after which the clinical pharmacy specialist assists with implementation of safety monitoring.

The clinical pharmacy specialist recommends absolute lymphocyte count (ALC) and liver function test (LFT) monitoring every 6 months while on fingolimod. At 6 months postinitiation, LFTs remain normal however, ALC falls to 300/µL. The patient denies any signs or symptoms of infection. The primary care provider orders a repeat complete blood count in 2 weeks and shows stable ALC, which remained at 300/µL.

Absolute lymphocyte count reduction is expected with fingolimod based on the mechanism of action of sequestering lymphocytes in lymphoid tissue and should not prompt therapy discontinuation. The lowest acceptable level of lymphopenia has been set to 200/µL because during clinical trials opportunistic infections were not seen even when the ALC dropped to this value. However risk of infection is unknown when ALCs are below this threshold as continuing fingolimod in this setting has not been extensively studied.\textsuperscript{54} If ALC values fall persistently below 200/µL, an alternative DMT should be considered. Holding fingolimod therapy to allow ALC to increase within an acceptable range may be tried. However, if treatment is interrupted for more than 14 days, FDO for cardiac changes is recommended upon reinitiation.

Siponimod and dimethyl fumarate can also reduce ALC.\textsuperscript{21,26} Because of a similar mechanism of action to fingolimod, ALC reduction with siponimod is expected and thus management recommendations are similar. Lymphopenia with dimethyl fumarate is less common. Unlike
fingolimod or siponimod where ALC returns to baseline soon after discontinuation, prolonged lymphopenia after discontinuation may occur with dimethyl fumarate. In addition, rare cases of progressive multifocal leukoencephalopathy (PML; a sometimes fatal opportunistic viral infection of the CNS) has been linked to dimethyl fumarate-induced lymphopenia, and a case of PML which occurred after an ALC of less than 500/μL that persisted for greater than 6 months prompted a FDA label change in 2014, which expands on lymphocyte monitoring recommendations. While severe lymphopenia as a risk factor for PML remains controversial, it does highlight the importance of appropriate laboratory monitoring and follow up.

**Patient Case Part 5: Rebound Relationships**

After 3 years on fingolimod the patient has had no relapses, no radiographic or clinical progression of disease, and ALCs have remained at or above 200/μL without any recent illnesses. Upon follow-up, the patient shares plans to relocate out of state for a new job opportunity in 2 months. This move will involve changing insurance providers and finding a new clinician. The patient is nervous about how to continue taking fingolimod until seen by a new clinician.

Fingolimod should not be abruptly discontinued without a plan to transition to an alternative DMT because of risk of rebound in persons with relapsing MS. Clinical rebound syndrome has been reported within 4 to 16 weeks of patients stopping fingolimod and is consistent with signs/symptoms of a severe clinical relapse such as drastic increases in new and/or enhancing lesions on MRI and new or worsening MS symptoms. Similarly, risk of disease rebound after discontinuation is also high with natalizumab as a number of case studies have reported an increase in disease activity beyond that of prenatalizumab levels. While the most effective management strategy to prevent rebound syndrome remains unclear, expert clinicians recommend transitioning to an alternative HE-DMT before the effects of fingolimod or natalizumab wear off. Based on experience, it is the authors’ practice to transition patients to a HE-DMT within 4 to 8 weeks after the last natalizumab infusion and within 4 weeks after the last fingolimod dose.

Since the patient will soon be without a clinician and possibly without fingolimod for an unknown length of time, switching to alternative HE-DMT prior to losing current insurance coverage would be ideal. Based on clinical experience, an anti-CD20 agent may be the best option given it may help prevent clinical rebound syndrome after discontinuing fingolimod. Anti-CD20 agents are HE-DMTs with clinical effects lasting for at least 6 months after receiving a dose, which allows the patient time to establish care. While the anti-CD20 agent, ocrelizumab, is FDA-approved for MS, rituximab was the precursor to its development and has been used off-label for many years in European countries and later in the United States. Either option would be appropriate, and choice would most likely be dictated by insurance coverage, copay, and provider preference.

**Conclusion**

The management of MS continues to rapidly evolve. Treatment options with greater efficacy and potential for altering the course are now available. Shared decision making and patient preferences remain key factors in DMT selection. However, treatment customization should also consider patient-specific negative prognostic factors both at diagnosis and throughout the course of treatment. Identification of these factors can further stratify therapy approach using the HE-DMTs, which then requires that benefits be balanced with sometimes very serious risks. Ongoing research will provide more direction as to which strategy is the safest and most effective for achieving a NEDA-like goal of treatment.

**References**

1. Costello K, Halper J, Kalb R, Skutnik L, Rapp R [Internet]. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition [updated 2019 Jun; cited 2019 Sep 14]. Available from: [http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf](http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf).
2. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27-40. DOI: 10.1111/ejn.14191. PubMed PMID: 3090457.
3. Reich DS, Luechini CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-80. DOI: 10.1056/NEJMra1401483. PubMed PMID: 29320652.
4. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622-36. DOI: 10.1016/S0140-6736(18)30481-1. PubMed PMID: 2957604.
5. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029-40. DOI: 10.1212/WNL.0000000000007035. PubMed PMID: 30774030.
6. National Multiple Sclerosis Society [Internet]. Who gets MS (epidemiology) [cited 2019 Sep 28]. Available from: https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS.
7. Cree BC, Gourraud P-A, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499-510. DOI: 10.1002/ana.24747. PubMed PMID: 27464262.
8. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. Brain. 1999;122(10):1941-50. DOI: 10.1093/brain/122.10.1941. PubMed PMID: 10506095.
9. Lublin FD. New Multiple sclerosis phenotype classification. Eur Neurol. 2014;72 Suppl 1:S1-5. DOI: 10.1159/000367614. PubMed PMID: 25278115.
10. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI: 10.1212/01.wnl.0000450560. PubMed PMID: 24871874.

11. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2021 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73. DOI: 10.1016/S1474-4422(17)30470-2. PubMed PMID: 29275977.

12. National Multiple Sclerosis Society [Internet]. Magnetic resonance imaging (MRI) [cited 2019 Sep 28]. Available from: https://www.nationalmssociety.org/Symptoms-Diagnosis/MRI.

13. National Multiple Sclerosis Society [Internet]. Multiple sclerosis and smoking [cited 2019 Sep 14]. Available from: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Research/Stroup_T_Smoking_and_MS_20151110.pdf.

14. National Multiple Sclerosis Society [Internet]. Vitamins, minerals & herbs in MS [cited 2019 Sep 14]. Available from: https://www.nationalmssociety.org/Programs-and-Services/Resources/Vitamins,-Minerals,-and-Herbs-in-MS-An-Introduction?page=3&bcorder=3&border-asc=1.

15. Bowen JD. Highly aggressive multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):689-714. DOI: 10.1212/CON.0000000000000731. PubMed PMID: 31162312.

16. Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scrl Relat Disord. 2019;30:215-24. DOI: 10.1016/j.msard.2019.01.039. PubMed PMID: 30826617.

17. Tyasabri [package insert]. Cambridge (MA): Biogen Idec; 2015.

18. Aubagio [package insert]. Cambridge (MA): Genzyme Corporation; 2014.

19. Ampyra [package insert]. Airdsley (NY): Acorda Therapeutics, Inc; 2014.

20. Ocrevus [package insert]. South San Francisco: Genentech, Inc; 2017.

21. Mayzent [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp; 2019.

22. Mavenclad [package insert]. Rockland (MA): EMD Serono, Inc; 2019.

23. Gilenya [package insert]. East Hanover (NJ): Novartis; 2014.

24. Copaxone [package insert]. North Wales (PA): Teva Pharmaceuticals; 2014.

25. Avonex [package insert]. Cambridge (MA): Biogen Idec; 2009.

26. Tecfidera [package insert]. Cambridge (MA): Biogen Idec; 2014.

27. Lemtrada [package insert]. Cambridge (MA): Genzyme Corporation; 2014.

28. Betaseron [package insert]. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc; 1993.

29. Rituxan [package insert]. South San Francisco: Biogen and Genentech Inc; 2009.

30. Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, et al. Real-life use of oral disease-modifying treatments in Austria. Acta Neurol Scand. 2019;140(1):32-9. DOI: 10.1111/ane.13097. PubMed PMID: 30958901.

31. Laplaud D-A, Casey R, Barbin L, Debouverie M, de Seze J, Brassat D, et al. Comparative effectiveness of teriflunomide vs beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol. 2005;12(6):425-31. DOI: 10.1111/j.1468-1331.2005.00396.x. PubMed PMID: 15885045.

32. Haas J, Finzlaß M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol. 2005;12(6):425-31. DOI: 10.1111/j.1468-1331.2005.00396.x. PubMed PMID: 15885045.

33. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Real-life use of oral disease-modifying treatments in Austria. Acta Neurol Scand. 2019;140(1):32-9. DOI: 10.1111/ane.13097. PubMed PMID: 30958901.

34. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cherian J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNb-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-83. DOI: 10.1212/01.wnl.0000345970.73354.17. PubMed PMID: 19279320.

35. Durelli L, Verdun E, Barbéro P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-60. DOI: 10.1016/S0140-6736(02)08340-1. PubMed PMID: 12288424.

36. Haas J, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10):1496-506. DOI: 10.1212/01.wnl.0000034080.43681.da. PubMed PMID: 12451188.

37. Ontaneda D, Nicholas J, Carraro M, Zhou H, Hou Q, Babb J, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation therapies in the US. Mult Scler Relat Disord. 2018;27:107-11. DOI: 10.1016/j.msard.2018.09.038. PubMed PMID: 29068221.

38. Vermersch P, Czonkowska A, Grimaldi LME, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705-16. DOI: 10.1177/1352458513507821. PubMed PMID: 24426064.

39. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khati BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(1):402-15. DOI: 10.1056/NEJMoa0907893. PubMed PMID: 20089554.

40. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97. DOI: 10.1056/NEJMoa1206328. PubMed PMID: 22932072.

41. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(12):1670-80. DOI: 10.1177/1352458517771504. PubMed PMID: 29353550.

42. Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. Mult Scler J Exp Transl Clin. 2017;3(3):205521737725102. DOI: 10.1177/205521737725102. PubMed PMID: 28839949.

43. Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler. 2018;24(12):1670-80. DOI: 10.1177/1352458517771504. PubMed PMID: 29353550.

44. Lu G, Beadall NH, Barton J, Hardy TA, Wang C, Barnett MH. The evolution of “No Evidence of Disease Activity” in multiple sclerosis. Mult Scler Relat Disord. 2018;20:231-8. DOI: 10.1016/j.msard.2017.12.016. PubMed PMID: 29576629.
47. Giovannoni G. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES. Mult Scler. 2016;22(11):1397-1400. DOI: 10.1177/1352458516650737. PubMed PMID: 27279588.

48. Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973-980. DOI: 10.1016/S1474-4422(19)30151-6. PubMed PMID: 31375366.

49. Tallantyre EC, Causon EG, Harding KE, Pickersgill TP, Robertson NP. The aetiology of acute neurological decline in multiple sclerosis: experience from an open-access clinic. Mult Scler. 2015;21(1):67-75. DOI: 10.1177/1352458514538333. PubMed PMID: 24948684.

50. Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Mult Scler Demyelinating Disord. 2018;3:Article5. DOI: 10.1186/s40893-018-0037-7.

51. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777-88. DOI: 10.1212/WNL.0000000000005347. PubMed PMID: 29686116.

52. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(4):98-108. DOI: 10.1007/s00415-005-0934-5. PubMed PMID: 16044212.

53. Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82(11):1344-50. DOI: 10.1136/jnnp.2010.229724. PubMed PMID: 21436229.

54. Thomas K, Ziemssen T. Management of fingolimod in clinical practice. Clin Neurol Neurosurg. 2013;115 Suppl 1:S60-4. DOI: 10.1016/j.clineuro.2013.09.023. PubMed PMID: 24321158.

55. Killestein J, Reder AT. Dimethyl fumarate-induced changes in the MS lymphocyte repertoire. Neurology. 2019;92(15):696-7. DOI: 10.1212/WNL.0000000000007255. PubMed PMID: 30918089.

56. Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790-4. DOI: 10.1001/jamaneurol.2016.0826. PubMed PMID: 27335594.

57. González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e00671. DOI: 10.1002/brb3.671. PubMed PMID: 28413713.

58. Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170-7. DOI: 10.1007/s00415-014-7325-8. PubMed PMID: 24728334.

59. Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074-81. DOI: 10.1212/WNL.0000000000003331. PubMed PMID: 27760868; PubMed Central PMCID: PMC5109942.